Analysis of G-Protein Coupled Receptor 30 (GPR30) on Endothelial Inflammation

  • Subhadeep Chakrabarti
  • Sandra T. DavidgeEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1366)


The female sex hormone estrogen (the most common form 17-β-estradiol or E2) is known to have both anti-inflammatory and pro-inflammatory effects. Given the diversity of estrogen responses mediated through its three distinct receptors, namely, estrogen receptor α (ERα), ERβ, and the G-protein coupled receptor 30 (GPR30), it is plausible that different receptors have specific modulatory effects on inflammation in different tissues. We have shown that activation of GPR30 exerted anti-inflammatory effects as demonstrated by significant attenuation of tumor necrosis factor (TNF)-mediated upregulation of adhesion molecules in isolated human umbilical vein endothelial cells. Interestingly, estrogen alone had no such effect and blockade of classical ERs restored the anti-inflammatory effect, suggesting that this effect was dependent on GPR30 and opposed to classical ERs. These findings were further validated by the negation of anti-inflammatory GPR30 effects by classical ER agonists. This chapter focuses on multiple pharmacological options to activate GPR30 and the use of TNF activated endothelial cells as a model system for inflammatory response as assessed by adhesion molecule detection through western blotting.

Key words

Estrogen Endothelium Inflammation GPER GPR30 TNF HUVEC PPT DPN G-1 G-15 



Dr. Davidge is a Canada Research Chair (CRC) in Maternal and Perinatal Cardiovascular Health. The Davidge laboratory receives funding from the Canadian Institutes of Health Research (CIHR), the Women and Children’s Health Research Institute (WCHRI) and the Heart and Stroke Foundation of Canada (HSF).


  1. 1.
    Regitz-Zagrosek V (2006) Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5:425–438CrossRefGoogle Scholar
  2. 2.
    Stork S, van der Schouw YT, Grobbee DE, Bots ML (2004) Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab 15:66–72CrossRefGoogle Scholar
  3. 3.
    Reslan OM, Khalil RA (2012) Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials 7:47–70CrossRefGoogle Scholar
  4. 4.
    Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE (2006) Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8:538–554CrossRefGoogle Scholar
  5. 5.
    Ba ZF, Chaudry IH (2008) Role of estrogen receptor subtypes in estrogen-induced organ-specific vasorelaxation after trauma-hemorrhage. Am J Physiol Heart Circ Physiol 295:H2061–H2067CrossRefGoogle Scholar
  6. 6.
    Chakrabarti S, Morton JS, Davidge ST (2014) Mechanisms of estrogen effects on the endothelium: an overview. Can J Cardiol 30:705–712CrossRefGoogle Scholar
  7. 7.
    Nilsson BO, Olde B, Leeb-Lundberg LM (2011) G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling. Br J Pharmacol 163:1131–1139CrossRefGoogle Scholar
  8. 8.
    Maggiolini M, Picard D (2010) The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 204:105–114CrossRefGoogle Scholar
  9. 9.
    Mizukami Y (2010) In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo. Endocr J 57:101–107CrossRefGoogle Scholar
  10. 10.
    Meyer MR, Prossnitz ER, Barton M (2011) The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol 55:17–25CrossRefGoogle Scholar
  11. 11.
    Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, Poynter JA, Meldrum DR (2010) Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 148:436–443CrossRefGoogle Scholar
  12. 12.
    Blasko E, Haskell CA, Leung S, Gualtieri G, Halks-Miller M, Mahmoudi M, Dennis MK, Prossnitz ER, Karpus WJ, Horuk R (2009) Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol 214:67–77CrossRefGoogle Scholar
  13. 13.
    Bodhankar S, Offner H (2011) Gpr30 forms an integral part of E2-protective pathway in experimental autoimmune encephalomyelitis. Immunol Endocr Metab Agents Med Chem 11:262–274CrossRefGoogle Scholar
  14. 14.
    Lu CL, Hsieh JC, Dun NJ, Oprea TI, Wang PS, Luo JC, Lin HC, Chang FY, Lee SD (2009) Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats. Gastroenterology 137:1040–1050CrossRefGoogle Scholar
  15. 15.
    Brunsing RL, Prossnitz ER (2011) Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1. Immunology 134:93–106CrossRefGoogle Scholar
  16. 16.
    Chakrabarti S, Davidge ST (2012) G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial inflammation. PLoS One 7:e52357CrossRefGoogle Scholar
  17. 17.
    Chakrabarti S, Chan CK, Jiang YY, Davidge ST (2012) Neuronal nitric oxide synthase regulates endothelial inflammation. J Leukoc Biol 91:947–956CrossRefGoogle Scholar
  18. 18.
    Majumder K, Chakrabarti S, Davidge ST, Wu J (2013) Structure and activity study of egg protein ovotransferrin derived peptides (IRW and IQW) on endothelial inflammatory response and oxidative stress. J Agric Food Chem 61:2120–2129CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Obstetrics & Gynecology, Women and Children’s Health Research Institute (WCHRI), Cardiovascular Research Centre and Mazankowski Alberta Heart InstituteUniversity of AlbertaEdmontonCanada
  2. 2.Department of Physiology, Women and Children’s Health Research Institute (WCHRI), Cardiovascular Research Centre and Mazankowski Alberta Heart InstituteUniversity of AlbertaEdmontonCanada

Personalised recommendations